The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis

by Hanny Al-Samkari, Jean M. Connors
Published 2018-08-01

Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia

by Hanny Al-Samkari, David J. Kuter
Published 2019-04-01

Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer Patients

by Orly Leiva, Jean M. Connors, Hanny Al-Samkari
Published 2020-07-01

Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features

by Abraham Z. Cheloff, David J. Kuter, Hanny Al‐Samkari
Published 2020-07-01

The role of romiplostim for pediatric patients with immune thrombocytopenia

by Hanny Al-Samkari, Rachael F. Grace, David J. Kuter
Published 2020-04-01

Response to rituximab in children and adults with immune thrombocytopenia (ITP)

by Emily M. Harris, Kirsty Hillier, Hanny Al‐Samkari, Laura Berbert, Rachael F. Grace
Published 2021-08-01

Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers

by Hanny Al-Samkari, Hasan A. Albitar, Scott E. Olitsky, Marianne S. Clancy, Vivek N. Iyer
Published 2019-11-01